Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Immatics US Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active. These actions are distributed between 2 distinct examiners and 2 distinct art units. GROOMS, TIFFANY NICOLE is the busiest examiner, with 1 pending office action. Each of the 2 pending office actions is being handled by a different examiner in a different art unit.
This means the company's Biotechnology & Pharmaceuticals technology is being reviewed across two separate technical classifications. GROOMS, TIFFANY NICOLE is responsible for 1 pending office action, which is a portion of the 2 pending office actions. The lack of overlap between examiners and art units for the 2 pending office actions suggests that the prosecution strategy must be tailored to two distinct sets of examiner expectations and art unit guidelines. Practitioners must manage the nuances of 2 distinct examiners while operating within the specific guidelines of the 2 distinct art units. This structure requires a tailored approach for each case to ensure progress.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| LU, CHENG | 1 | 54.1% | +64.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18309062 | DOMINANT NEGATIVE TGFBETA RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF | GROOMS, TIFFANY NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18053705 | ADOPTIVE CELL THERAPY COMBINATION TREATMENT AND COMPOSITIONS THEREOF | LU, CHENG | 6d |
| 18309062 | DOMINANT NEGATIVE TGFBETA RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF | GROOMS, TIFFANY NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18309062 | DOMINANT NEGATIVE TGFBETA RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF | GROOMS, TIFFANY NICOLE | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18053705 | ADOPTIVE CELL THERAPY COMBINATION TREATMENT AND COMPOSITIONS THEREOF | LU, CHENG | 1642 | §103DP | Final Rejection | 6d | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial